Terms: = Prostate cancer AND ACSL3, PRO2194, 2181, ENSG00000123983, O95573, FACL3, ACS3 AND Diagnosis
4 results:
1. Comparison of Magnetic Resonance Imaging-Based Risk Calculators to Predict prostate cancer Risk.
Patel HD; Remmers S; Ellis JL; Li EV; Roobol MJ; Fang AM; Davik P; Rais-Bahrami S; Murphy AB; Ross AE; Gupta GN
JAMA Netw Open; 2024 Mar; 7(3):e241516. PubMed ID: 38451522
[TBL] [Abstract] [Full Text] [Related]
2. May non-metastatic clinically localized castration-resistant prostate cancer after primary androgen ablation benefit from salvage prostate radiotherapy?
Botticella A; Guarneri A; Filippi AR; Levra NG; Munoz F; Ragona R; Gontero P; Ricardi U
J Cancer Res Clin Oncol; 2013 Nov; 139(11):1955-60. PubMed ID: 24057645
[TBL] [Abstract] [Full Text] [Related]
3. [prostate cancer management and factors associated with radical prostatectomy in France in 2001].
Jegu J; Tretarre B; Velten M; Guizard AV; Danzon A; Buemi A; Colonna M; Kadi-Hanifi AM; Ganry O; Molinie F; Bara S; Rebillard X; Grosclaude P
Prog Urol; 2010 Jan; 20(1):56-64. PubMed ID: 20123529
[TBL] [Abstract] [Full Text] [Related]
4. Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer.
Attard G; Clark J; Ambroisine L; Mills IG; Fisher G; Flohr P; Reid A; Edwards S; Kovacs G; Berney D; Foster C; Massie CE; Fletcher A; De Bono JS; Scardino P; Cuzick J; Cooper CS;
Br J Cancer; 2008 Jul; 99(2):314-20. PubMed ID: 18594527
[TBL] [Abstract] [Full Text] [Related]
